Fausto Castagnetti

7.9k total citations
109 papers, 2.8k citations indexed

About

Fausto Castagnetti is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Fausto Castagnetti has authored 109 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Hematology, 87 papers in Genetics and 49 papers in Rheumatology. Recurrent topics in Fausto Castagnetti's work include Chronic Myeloid Leukemia Treatments (99 papers), Chronic Lymphocytic Leukemia Research (86 papers) and Eosinophilic Disorders and Syndromes (49 papers). Fausto Castagnetti is often cited by papers focused on Chronic Myeloid Leukemia Treatments (99 papers), Chronic Lymphocytic Leukemia Research (86 papers) and Eosinophilic Disorders and Syndromes (49 papers). Fausto Castagnetti collaborates with scholars based in Italy, Germany and United States. Fausto Castagnetti's co-authors include Michele Baccarani, Gianantonio Rosti, Gabriele Gugliotta, Simona Soverini, Giovanni Martinelli, Francesca Palandri, Giuseppe Saglio, Marilina Amabile, Fabrizio Pane and Ilaria Iacobucci and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Fausto Castagnetti

105 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fausto Castagnetti Italy	27	2.4k	2.0k	1.2k	343	313	109	2.8k
Elisabetta Abruzzese Italy	27	2.5k 1.1×	1.8k 0.9×	1.1k 0.9×	399 1.2×	456 1.5×	150	3.2k
Susanne Saußele Germany	30	3.0k 1.3×	2.4k 1.2×	1.4k 1.1×	396 1.2×	403 1.3×	127	3.5k
Kerry Taylor Australia	12	1.6k 0.7×	1.1k 0.6×	712 0.6×	260 0.8×	155 0.5×	28	2.0k
Juan Luis Steegmann Spain	20	1.9k 0.8×	1.6k 0.8×	929 0.7×	177 0.5×	220 0.7×	73	2.3k
Valentín García‐Gutiérrez Spain	20	1.7k 0.7×	1.4k 0.7×	768 0.6×	256 0.7×	162 0.5×	104	2.0k
P. Le Coutre Germany	5	1.3k 0.6×	1.1k 0.5×	673 0.5×	143 0.4×	158 0.5×	5	1.6k
Clarisse Lobo Brazil	12	1.3k 0.5×	1.1k 0.6×	647 0.5×	144 0.4×	145 0.5×	24	1.5k
Lydia Wunderle Germany	9	1.2k 0.5×	739 0.4×	538 0.4×	193 0.6×	464 1.5×	17	1.5k
Pascale Cony‐Makhoul France	24	1.3k 0.5×	864 0.4×	502 0.4×	257 0.7×	191 0.6×	76	1.5k
Sandip Shah India	11	1.1k 0.5×	880 0.4×	549 0.4×	138 0.4×	153 0.5×	50	1.4k

Countries citing papers authored by Fausto Castagnetti

Since Specialization

Citations

This map shows the geographic impact of Fausto Castagnetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fausto Castagnetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fausto Castagnetti more than expected).

Fields of papers citing papers by Fausto Castagnetti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fausto Castagnetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fausto Castagnetti. The network helps show where Fausto Castagnetti may publish in the future.

Co-authorship network of co-authors of Fausto Castagnetti

This figure shows the co-authorship network connecting the top 25 collaborators of Fausto Castagnetti. A scholar is included among the top collaborators of Fausto Castagnetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fausto Castagnetti. Fausto Castagnetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tassinari, Elisa, Francesco Porta, Valerio Di Scioscio, et al.. (2023). Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report. Frontiers in Oncology. 13. 1310452–1310452.

Rosti, Gianantonio, Tim H. Brümmendorf, Bjørn Tore Gjertsen, et al.. (2023). Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study. Leukemia. 38(1). 126–135. 3 indexed citations

Breccia, Massimo, Alfonso Piciocchi, Elisabetta Abruzzese, et al.. (2023). Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey. Journal of Clinical Medicine. 12(16). 5267–5267. 1 indexed citations

Soverini, Simona, Maurizio Martelli, Fausto Castagnetti, et al.. (2022). Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia. Leukemia. 36(9). 2250–2260. 14 indexed citations

Baccarani, Michele, Francesca Bonifazi, Simona Soverini, et al.. (2022). Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia. Leukemia. 36(5). 1227–1236. 6 indexed citations

Gaibani, Paolo, Chiara Sartor, Simone Ambretti, et al.. (2020). Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients. Microorganisms. 8(12). 2055–2055. 5 indexed citations

Cottone, Francesco, Gary S. Collins, Amélie Anota, et al.. (2020). Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies. Journal of Clinical Epidemiology. 127. 9–18. 9 indexed citations

Breccia, Massimo, Francesca Palandri, Luigiana Luciano, et al.. (2018). Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. Annals of Hematology. 97(5). 745–754. 7 indexed citations

Hochhaus, Andreas, Philipp le Coutre, L. N. Petrov, et al.. (2017). Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. Journal of Cancer Research and Clinical Oncology. 143(7). 1225–1233. 6 indexed citations

10.

Mancini, Manuela, Ken‐Ichi Takemaru, Fausto Castagnetti, et al.. (2015). 14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia. PLoS ONE. 10(7). e0131074–e0131074. 14 indexed citations

11.

Baccarani, Michele, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, & Gianantonio Rosti. (2014). TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases. 6(1). e2014005–e2014005. 31 indexed citations

12.

Gugliotta, Gabriele, Fausto Castagnetti, Miriam Fogli, et al.. (2013). Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. Expert Review of Hematology. 6(5). 563–574. 18 indexed citations

13.

Mancini, Manuela, Ken‐Ichi Takemaru, Enrica Borsi, et al.. (2013). Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells. Cellular Signalling. 25(9). 1820–1827. 16 indexed citations

14.

Defina, Marzia, Alessandro Gozzetti, Elisabetta Abruzzese, et al.. (2012). Evaluation of residual CD34⁺Ph⁺ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first‐line nilotinib therapy. Cancer. 118(21). 5265–5269. 10 indexed citations

15.

Lemoli, Roberto M., Valentina Salvestrini, Elisa Bianchi, et al.. (2009). Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34− cell population with intrinsic resistance to imatinib. Blood. 114(25). 5191–5200. 58 indexed citations

16.

Castagnetti, Fausto, Francesca Palandri, Gabriele Gugliotta, et al.. (2009). Thyrosin kinase inhibitors: nilotinib. 2(5). 22–26. 1 indexed citations

17.

Martinelli, Giovanni, Ilaria Iacobucci, Simona Soverini, et al.. (2007). Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance.. Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna). 11 indexed citations

18.

Soverini, Simona, Giovanni Martinelli, Sabrina Colarossi, et al.. (2007). Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. The Lancet Oncology. 8(3). 273–274. 30 indexed citations

19.

Soverini, Simona, Sabrina Colarossi, Alessandra Gnani, et al.. (2007). Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 92(3). 401–404. 133 indexed citations

20.

Martinelli, Giovanni, Ilaria Iacobucci, Gianantonio Rosti, et al.. (2006). Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Annals of Oncology. 17(3). 495–502. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact